Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings Inc (OBIO) delivers innovative biomedical solutions through strategic partnerships, focusing on cardiovascular therapies like cardiac neuromodulation and drug-coated balloon systems. This page provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and collaborative developments.
Access real-time updates on OBIO's pioneering work in BackBeat Cardiac Neuromodulation Therapy and Virtue SAB technology. Our news collection covers partnership expansions with industry leaders, trial result announcements, and financial disclosures critical for evaluating the company's progress in treating hypertension and vascular disease.
Key updates include progress reports on late-stage clinical trials, analysis of strategic risk-sharing partnerships, and manufacturing scale-up initiatives for global commercialization. All content is vetted for accuracy and presented in compliance-conscious format suitable for both institutional investors and healthcare stakeholders.
Bookmark this page for streamlined tracking of OBIO's pipeline developments and partnership-driven growth strategy. For comprehensive insights into biomedical innovation and investment considerations, revisit regularly as new information becomes available.
Orchestra BioMed (NASDAQ: OBIO) announced a satellite symposium at the HRS 2025 Annual Meeting focusing on their atrioventricular interval modulation (AVIM) therapy program. The FDA recently granted Breakthrough Device Designation for AVIM therapy, targeting patients with uncontrolled hypertension and increased cardiovascular risk.
The symposium, scheduled for April 25, 2025, in San Diego, will feature presentations from leading experts discussing clinical results showing AVIM therapy's effectiveness in reducing systolic blood pressure and improving cardiac function. Orchestra BioMed estimates over 7.7 million U.S. patients meet the criteria for AVIM therapy.
The company is currently enrolling patients in the BACKBEAT global pivotal study in collaboration with Medtronic (NYSE: MDT), evaluating AVIM therapy for uncontrolled hypertension in patients with dual-chamber pacemakers.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.
Orchestra BioMed (Nasdaq: OBIO) has received FDA Breakthrough Device Designation (BDD) for its atrioventricular interval modulation (AVIM) therapy. The designation applies to an estimated 7.7 million U.S. patients with uncontrolled hypertension and increased cardiovascular risk.
The AVIM therapy, delivered through an implantable pacemaker system, is designed for patients with preserved left ventricular systolic function and uncontrolled hypertension, despite using anti-hypertensive medications. The company is currently conducting the BACKBEAT global pivotal study in collaboration with Medtronic (NYSE: MDT).
The BDD status provides accelerated FDA engagement and reviews, while potentially supporting higher reimbursement for AVIM-enabled devices through Medicare's New Technology Add-on Payment and Transitional Pass-Through payments programs.
Orchestra BioMed (NASDAQ: OBIO) has reported its full year 2024 financial results, showing a revenue of $2.6 million, down from $2.8 million in 2023. The company's net loss widened to $61.0 million ($1.66 per share) compared to $49.1 million in 2023.
Key financial metrics include cash and marketable securities of $66.8 million as of December 31, 2024. R&D expenses increased to $42.8 million from $33.8 million, primarily due to the BACKBEAT global pivotal study costs. The company raised approximately $30 million through stock sales and credit facility.
Notable developments include continued progress on the BACKBEAT study with Medtronic, submission of a revised design for the Virtue ISR-US pivotal study, and entering mediation with Terumo for partnership restructuring. The company also strengthened its leadership with three new independent directors and appointed Mark Pomeranz as EVP & General Manager of Interventional Therapies.
Orchestra BioMed Holdings (Nasdaq: OBIO) has announced its participation in several upcoming investor conferences in early 2025. The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET, and the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, at 8:00 AM ET.
The TD Cowen presentation will be available via webcast, accessible through Orchestra BioMed's website investor section, with replays available for 90 days after the event. Additionally, the company will host one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.
Orchestra BioMed Holdings (Nasdaq: OBIO) has appointed Dr. Vivek Reddy as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. Dr. Reddy, currently Director of Cardiac Arrhythmia Services at Mount Sinai, will lead the execution of the BACKBEAT global pivotal study, which evaluates the efficacy and safety of atrioventricular interval modulation (AVIM) therapy for patients with uncontrolled hypertension and pacemaker indication.
The AVIM therapy represents a potential always-on, adjustable hypertension treatment that doesn't rely on patient adherence. Dr. Reddy will focus on completing the BACKBEAT study and coordinating efforts among clinical advisors to realize AVIM therapy's potential for hypertension populations with increased cardiovascular risk. The company is also exploring additional therapeutic applications for this technology.
Orchestra BioMed (NASDAQ: OBIO) announced late-breaking data showing favorable effects of atrioventricular interval modulation (AVIM) therapy on diastolic dysfunction in hypertensive patients. The retrospective analysis of the MODERATO II study revealed that AVIM therapy significantly improved echocardiographic markers of diastolic dysfunction, a key factor in heart failure development.
Key findings from the study of 36 patients with sufficient Echo data (61% with diastolic dysfunction) showed that AVIM therapy reduced ambulatory systolic blood pressure by 8.3±9.7 mmHg in treated patients versus 2.2±9.8 mmHg in the control group. Office systolic blood pressure decreased by 12.1±12.8 mmHg in treated patients compared to an increase of 2.9±26.4 mmHg in controls.
The therapy also demonstrated significant improvements in key measures of diastolic function, including increased e' (from 5.9±2.0 to 8.8±3.4cm/sec) and E/A ratio (from 0.86±0.39 to 1.60±0.84), indicating improved left ventricular relaxation and filling.
Orchestra BioMed Holdings (NASDAQ: OBIO) has appointed Christopher Cleary to its Board of Directors as an independent member, effective January 30, 2025. Cleary, former Senior Vice President of Corporate Development at Medtronic, brings over three decades of experience in corporate development, M&A, and R&D collaborations.
During his tenure at Medtronic, Cleary facilitated over 35 acquisitions and orchestrated the $6 billion sale of Covidien Group's medical supply assets to Cardinal Health. He previously served as CEO of Alesia Capital Services and led M&A teams at GE Capital, closing acquisitions totaling more than $60 billion across 200+ transactions globally.
Additionally, Eric A. Rose, M.D. will transition from Board Member to Board Member Emeritus and Strategic Advisor after seven years of service, continuing to provide expertise and guidance to Orchestra BioMed.
Orchestra BioMed (Nasdaq: OBIO) announced two presentations at the 2024 Innovation in Cardiology Intervention (ICI) meeting in Tel Aviv. The presentations focus on the BACKBEAT global pivotal study and AVIM therapy for treating uncontrolled hypertension in patients requiring dual-chamber pacemakers.
Dr. Avi Fischer will present insights on the unmet medical needs of pacemaker patients with uncontrolled hypertension. Dr. Andrea Russo will discuss AVIM therapy's mechanism of action and clinical evidence, including results from the MODERATO I and II pilot studies, demonstrating how the therapy modulates the autonomic nervous system to reduce blood pressure.
Orchestra BioMed Holdings (Nasdaq: OBIO) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York, NY from December 3-5, 2024. The company's management will deliver a fireside chat presentation on Wednesday, December 4, 2024, at 3:00 PM EST. The presentation will be available via webcast, with a replay accessible on the Orchestra BioMed website's Events section for 90 days afterward. The company will also be available for one-on-one meetings during the conference.
